STOCK TITAN

Aadi Bioscience, Inc. - $AADI STOCK NEWS

Welcome to our dedicated page for Aadi Bioscience news (Ticker: $AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aadi Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aadi Bioscience's position in the market.

Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announces participation in investor events: H.C. Wainwright 25th Annual Global Investment Conference and Morgan Stanley 21st Annual Global Healthcare Conference. CEO and CFO will present and participate in fireside chat respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences
-
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) reports a 6% increase in FYARRO sales to $6.2 million in 2Q 2023, with plans for an interim analysis on 40 patients in the PRECISION1 trial before the end of 2023. The company is expanding its pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Aadi Bioscience, Inc.

Nasdaq:AADI

AADI Rankings

AADI Stock Data

52.05M
16.00M
12.45%
52.87%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PACIFIC PALISADES

About AADI

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n